J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 C l i n i c a l t r i a l s
2 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
P l e c t a s i n
3 l a n g u a g e s
● ا ل ع ر ب ي ة ● D e u t s c h ● F r a n ç a i s
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Clinical trials [ edit ]
Pre-clinical tests in mice have shown promising results in that multiresistant bacteria have problems mutating resistance against plectasin,[3] [4] [5]
At the end of 2008, Novozymes signed a global licensing agreement with Sanofi-Aventis for the further development and marketing of NZ2114, a derivative of plectasin, as a treatment for gram-positive bacterial infections, e.g. Streptococcus and Staphylococcus which are resistant to all existing antibiotics.[2] [6]
References [ edit ]
^ Mygind, Per H.; Fischer, Rikke L.; Schnorr, Kirk M.; Hansen, Mogens T.; Sönksen, Carsten P.; Ludvigsen, Svend; Raventós, Dorotea; Buskov, Steen; Christensen, Bjarke; De Maria, Leonardo; Taboureau, Olivier (2005). "Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus". Nature . 437 (7061): 975–980. Bibcode :2005Natur.437..975M . doi :10.1038/nature04051 . ISSN 1476-4687 . PMID 16222292 . S2CID 4423851 .
^ a b "Novozymes reveals knowledge on new antibiotic against resistant bacteria" . Novozymes . 2010-05-28. Retrieved 2010-05-28 .
^ "Plectasin NZ2114 - Novel Microbial Agent" . Drug Development Technology . Retrieved 2010-05-28 .
^ Kristensen, HH; et al. (2010). "Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II". Science . 328 (5982): 1168–1172. Bibcode :2010Sci...328.1168S . doi :10.1126/science.1185723 . hdl :1874/202594 PMID 20508130 . S2CID 206524928 .
^ Jekhmane, S., Derks. M. (2024). "Host defence peptide plectasin targets bacterial cell wall precursor lipid II by a calcium-sensitive supramolecular mechanism" . Nature Microbiology . doi :10.1038/s41564-024-01696-9 PMC 11222147 PMID 38783023 . {{cite journal }}: CS1 maint: multiple names: authors list (link )
^ Kristensen, HH; et al. (2009). "In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model" . Antimicrob. Agents Chemother . 53 7 ): 3003–3009. doi :10.1128/AAC.01584-08 . PMC 2704636 PMID 19414576 .
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Plectasin&oldid=1233261963 " C a t e g o r i e s : ● A n t i b i o t i c s ● P e p t i d e s ● D e f e n s i n s ● A n t i b i o t i c s t u b s H i d d e n c a t e g o r i e s : ● C S 1 m a i n t : m u l t i p l e n a m e s : a u t h o r s l i s t ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● A l l a r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s ● A r t i c l e s w i t h u n s o u r c e d s t a t e m e n t s f r o m J a n u a r y 2 0 2 3 ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 8 J u l y 2 0 2 4 , a t 0 4 : 3 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
